• SPX
  • 6090.27
  • 0.25 %
  • 15.1602
  • DJI
  • 44642.52
  • -0.28 %
  • -123.1914
  • N225
  • 39160.5
  • 0.18 %
  • 69.3281
  • FTSE
  • 8308.61
  • -0.49 %
  • -40.7695
  • IXIC
  • 19859.773
  • 0.81 %
  • 159.0508
Lantern Pharma Inc. (LTRN) Stock Price, News & Analysis

Lantern Pharma Inc. (LTRN) Stock Price, News & Analysis

Currency in USD Disclaimer

$3.98

$0.48

(13.57%)

Day's range
$3.52
Day's range
$4.15
50-day range
$2.79
Day's range
$4.15
  • Country: US
  • ISIN: US51654W1018
52 wk range
$2.79
Day's range
$11.99


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 2.46
  • Piotroski Score 3.00
  • Grade Buy
  • Symbol (LTRN)
  • Company Lantern Pharma Inc.
  • Price $3.98
  • Changes Percentage (13.57%)
  • Change $0.48
  • Day Low $3.52
  • Day High $4.15
  • Year High $11.99

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/06/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.62
  • Trailing P/E Ratio -3.44
  • Forward P/E Ratio -3.44
  • P/E Growth -3.44
  • Net Income $-15,961,534

Income Statement

Quarterly

Annual

Latest News of LTRN

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Lantern Pharma Inc. Frequently Asked Questions

  • What were the earnings of LTRN in the last quarter?

    In the last quarter Lantern Pharma Inc. earnings were on Thursday, November, 7th. The Lantern Pharma Inc. maker reported -$0.42 EPS for the quarter, beating analysts' consensus estimates of -$0.56 by $0.14.

  • What is the Lantern Pharma Inc. stock price today?

    Today's price of Lantern Pharma Inc. is $3.98 — it has increased by +13.57% in the past 24 hours. Watch Lantern Pharma Inc. stock price performance more closely on the chart.

  • Does Lantern Pharma Inc. release reports?

    Yes, you can track Lantern Pharma Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Lantern Pharma Inc. stock forecast?

    Watch the Lantern Pharma Inc. chart and read a more detailed Lantern Pharma Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Lantern Pharma Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Lantern Pharma Inc. stock ticker.

  • How to buy Lantern Pharma Inc. stocks?

    Like other stocks, LTRN shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Lantern Pharma Inc.'s EBITDA?

    Lantern Pharma Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Lantern Pharma Inc.’s financial statements.

  • What is the Lantern Pharma Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Lantern Pharma Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Lantern Pharma Inc.'s financials relevant news, and technical analysis. Lantern Pharma Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Lantern Pharma Inc. stock currently indicates a “sell” signal. For more insights, review Lantern Pharma Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.